Drug Database · Clinicians

Proparacaine

Brands (2) Alcaine, PrimaxShow all

Local anaesthetic; Local anesthetic PH FDA category

Rx · Prescription drug2 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 0c0fa0bf-977d-4539-b8dc-54c187c5b094, version date June 10, 2026 (Alcaine · Alcon Laboratories, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE: ALCAINE™ ophthalmic solution is indicated for procedures in which a topical ophthalmic anesthetic is indicated: corneal anesthesia of short duration, e.g. tonometry, gonioscopy, removal of corneal…
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE: ALCAINE™ ophthalmic solution is indicated for procedures in which a topical ophthalmic anesthetic is indicated: corneal anesthesia of short duration, e.g. tonometry, gonioscopy, removal of corneal foreign bodies, and for short corneal and conjunctival procedures.

Contraindications

CONTRAINDICATIONS: ALCAINE™ ophthalmic solution should be considered contraindicated in patients with known hypersensitivity to any of the ingredients of this preparation.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION: Usual Dosage: Removal of foreign bodies and sutures, and for tonometry: 1 to 2 drops (in single instillations) in each eye before operating. Short Corneal and Conjunctival Procedures: 1 drop in each eye every 5 to 10 minutes for 5 to 7 doses. NOTE: ALCAINE™ (proparacaine hydrochloride ophthalmic solution, USP) 0.5% should be clear to straw-color. If the solution becomes darker, discard the solution.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use: Safety and effectiveness of proparacaine hydrochloride ophthalmic solution in pediatric patients have been established. Use of proparacaine hydrochloride is supported by evidence from adequate and well-controlled studies in adults and children over the age of twelve, and safety information in neonates and other pediatric patients.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use: No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.

Dosage forms

Philippines

  • Ophthalmic solution: 5 mg/mL
  • Sterile ophthalmic solution: 5 mg/mL

Registered products in the Philippines

2 products registered with the Food and Drug Administration (FDA) Philippines list Proparacaine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Proparacaine
Package insert
AlcaineProparacaine Hydrochloride
5mg/mL (0.5%) Sterile Ophthalmic SolutionPlastic Droptainer Dispenser x 15 mL (Box of 1's)
Rx
Alcon Research, LLCU.S.A
Importer: Alcon Laboratories (Phils), Inc.
DR-XY13591
Oct 4, 2027
PrimaxProparacaine Hydrochloride
5 mg/mL (0.5%) Ophthalmic Solution (Eye Drops)LDPE White Bottle x 10 mL (Box of 1’s)
Rx
Laboratorios Ashford Lda.China
Marrion Pharma Inc.
DR-XY36929
Feb 9, 2037

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS: NOT FOR INJECTION - FOR TOPICAL OPHTHALMIC USE ONLY. Prolonged use of a topical ocular anesthetic is not recommended. It may produce permanent corneal opacification with accompanying visual loss. ALCAINE™ ophthalmic solution is indicated for administration under the direct supervision of a healthcare provider. ALCAINE™ ophthalmic solution is not intended for patient self-administration.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS: Occasional temporary stinging, burning and conjunctival redness may occur with the use of proparacaine. Corneal edema has been reported following the use of proparacaine. A rare, severe, immediate-type, apparently hyperallergic corneal reaction characterized by acute, intense and diffuse epithelial keratitis, a gray, ground glass appearance, sloughing of large areas of necrotic epithelium, corneal filaments and, sometimes, iritis with descemetitis has been reported.

Allergic contact dermatitis from proparacaine with drying and fissuring of the fingertips has also been reported.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy: Animal reproduction studies have not been conducted with ALCAINE ™ (proparacaine hydrochloride ophthalmic solution, USP) 0.5%. It is also not known whether proparacaine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Proparacaine hydrochloride should be administered to a pregnant woman only if clearly needed.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when proparacaine hydrochloride is administered to a nursing woman.

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY: ALCAINE™ ophthalmic solution is a rapidly-acting topical anesthetic, with induced anesthesia lasting approximately 10-20 minutes.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Alcaine · Alcon Laboratories, Inc. [US FDA-approved label, version 12, June 10, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c0fa0bf-977d-4539-b8dc-54c187c5b094
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .